Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 8 pages
Data source: Published sources
Share a link:
https://casecent.re/p/54668
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
By the turn of the 21st century, despite investing $7 billion a year on R&D, Pfizer has been witnessing constant decline in its productivity. Since 2001, Pfizer''s shares have declined by 45% to $25 a share. Analysts estimate flat earnings for Pfizer in 2005 and 1.5% annual decline in its sales through 2010. Under such circumstances, Pfizer has initiated a comprehensive review of its business and the company is expected to undergo a major restructuring in 2005. The case study, while highlighting the challenges faced by Pfizer due to lack of new products in its pipeline, triggers discussion on the future strategies Pfizer would adopt to retain its market position.
About
Abstract
By the turn of the 21st century, despite investing $7 billion a year on R&D, Pfizer has been witnessing constant decline in its productivity. Since 2001, Pfizer''s shares have declined by 45% to $25 a share. Analysts estimate flat earnings for Pfizer in 2005 and 1.5% annual decline in its sales through 2010. Under such circumstances, Pfizer has initiated a comprehensive review of its business and the company is expected to undergo a major restructuring in 2005. The case study, while highlighting the challenges faced by Pfizer due to lack of new products in its pipeline, triggers discussion on the future strategies Pfizer would adopt to retain its market position.